Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Breast Neoplasms 3Drug-Related Side Effects and Adverse Reactions 2Breast Neoplasms, Male 2Rectal Neoplasms 1Ovarian Neoplasms 1Hand-Foot Syndrome 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4Capecitabine 4pembrolizumab 3Trastuzumab 3Methods 3Magnetic Resonance Spectroscopy 3Irinotecan 3Gemcitabine 3Counseling 3trametinib 2palbociclib 2cediranib 2Standard of Care 2Mental Status and Dementia Tests 2Fluorodeoxyglucose F18 2Docetaxel 2Cyclophosphamide 2Biopsy 22,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 2veliparib 1ulixertinib 1trastuzumab biosimilar HLX02 1tipifarnib 1spartalizumab 1sargramostim 1sapanisertib 1relatlimab 1pertuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Pyridoxine × Breast × Clear all
NCT00559858 2013-08-02

Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine for Advanced Colorectal Cancer or Breast Cancer

National Cancer Institute (NCI)

Phase 3 Unknown
270 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Breast Neoplasms, Male, Hand-Foot Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡